Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Redsense Medical AB (RDSNF) fair value: what the stock is really worth
As of Jun 2, 2026: fair value of Redsense Medical AB $0.11, price $0.51, upside -78.4%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
RM
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
Redsense Medical AB
RDSNF · USWeakest SetupStrongly overvalued and low quality.
!Fair value $0.1100 · Strongly overvalued (−78.4%)
!Quality 34/100
!Expensive Growth (revenue 5y +10.7 %/yr)
!Loss-making · -10.1% net margin (TTM)
!Low debt · negative free cash flow
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch Redsense Medical AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
32‑month range $0.5100 – $1.05 · fair‑value band $0.0700 – $0.1400 · the $0.5100 price screens above the $0.1100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Redsense Medical AB (publ) provides an alarm in the event of blood leakage to monitor hemodialysis treatments in Europe, Canada, and Australia.
Show more
Redsense Medical AB (publ) provides an alarm in the event of blood leakage to monitor hemodialysis treatments in Europe, Canada, and Australia. It offers alarm units, such as Redsense, an alarm system for monitoring the blood access during hemodialysis; sensor patches to monitor venous needle or catheter access; and Redsense clamps to automatically stop the blood flow. The company was founded in 2000 and is headquartered in Halmstad, Sweden.
Stock analysis
Redsense Medical AB (RDSNF) currently trades at $0.5100, while our model-based Fair Value estimate is $0.1100, 78.4% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0700 (bear) to $0.1400 (bull), the price of $0.5100 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Redsense Medical AB reported revenue of 24.0M SEK in FY2025 versus 9.4M SEK in FY2021, a compound +26.6%/yr. Reported net income was −7.2M SEK in FY2025.
Key figures
Market cap $8.4M · P/S ratio 0.26 · EPS (TTM) $−0.0300 · Net margin −29.9% · Return on equity −8.0% · Return on assets (EBIT) −19.7% · Revenue (TTM) 31.8M SEK · Revenue growth (YoY) +38.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −78%, RDSNF screens richer than that median.
Fair Value models
Bear $0.0700
Fair Value $0.1100
Bull $0.1400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham)
$0.1000
$0.1400
$0.2100
53
All 1 models by family
Asset-Based
NCAV (Graham)
$0.1000
$0.1400
$0.2100
53
Notify me when RDSNF reaches fair value
Put RDSNF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
34/100
Of which business quality 38 · Market factors (momentum, volatility) 56
Profitability
23
Margins and returns on capital today
Quality Growth
19
Are margins and returns improving?
Cashflow
5
Earnings quality: real cash, not paper profit
Fin. Strength
79
Balance sheet, leverage, solvency risk
Investment
54
Disciplined investing over empire-building
Low Volatility
100
Calm price path (market factor)
Momentum
40
Price trend over the last 3–12 months (market factor)
52W Momentum
33
Distance to the 52-week high (market factor)
Net Issuance
53
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−14.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−56.3% (2020) → −30.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
RDSNF screens overvalued: fair value 78% below the price. Compare with Abbott Laboratories, →
Compare Redsense Medical AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 350 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Edwards Lifesciences Corporation EW | $85.19 | $81.94 | −4% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| Koninklijke Philips N.V PHIA | €21.87 | €15.23 | −30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Redsense Medical AB (RDSNF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1100 versus the last price from Jun 2, 2026 of $0.5100, about −78% upside (overvalued).
What is the fair value of RDSNF?
Our model-based fair value for Redsense Medical AB is $0.1100 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jun 2, 2026): $0.5100.
What is the quality score of RDSNF?
Redsense Medical AB has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Redsense Medical AB (RDSNF)?
Our model-based price target is the fair value of $0.1100 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.0700, optimistic scenario $0.1400. It is a calculation from audited fundamentals, not an analyst target.
What is the Redsense Medical AB stock forecast for 2026?
Our models put fair value at $0.1100, about −78% upside versus the last price from Jun 2, 2026 of $0.5100 (overvalued). Cautious scenario $0.0700, optimistic scenario $0.1400. The calculation is refreshed regularly with new filings.
What is the revenue of Redsense Medical AB (RDSNF)?
Redsense Medical AB reported trailing-twelve-month revenue of about 31.8M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Redsense Medical AB (RDSNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Redsense Medical AB it is $0.1100 per share (as of Sep 24, 2026), against a price of $0.5100. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Redsense Medical AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RDSNF trades above its calculated fair value: price $0.5100, fair value $0.1100, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RDSNF?
No. The price is what the market pays today ($0.5100); the fair value is what the company's own numbers justify ($0.1100). For Redsense Medical AB the two are $0.4000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Redsense Medical AB worth?
The market values Redsense Medical AB at about $8.4M (market capitalisation, as of Sep 24, 2026). Per share that is $0.5100; our models calculate a fair value of $0.1100 per share.
What do the bullish and bearish scenarios say about RDSNF?
Our models span a range for Redsense Medical AB: cautious scenario $0.0700, base $0.1100, optimistic $0.1400 per share (as of Sep 24, 2026, price $0.5100). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Redsense Medical AB (RDSNF)?
Balance-sheet figures for Redsense Medical AB (as of Sep 24, 2026): return on equity −8.0%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is RDSNF from its 52-week high?
Redsense Medical AB trades at $0.5100, at its 52-week high of $0.5100 and at the low of $0.5100 (as of Jun 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1100 is for.
Which stocks are comparable to Redsense Medical AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Redsense Medical AB stock attractive at the current price?
The data as of Sep 24, 2026: price $0.5100, calculated fair value $0.1100 (−78%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RDSNF calculated?
We run Redsense Medical AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Redsense Medical AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Redsense Medical AB (RDSNF)?
The latest price we hold is from Jun 2, 2026 and stands at $0.5100. Our model-based fair value is $0.1100, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Redsense Medical AB right now?
The price sits above even our optimistic bull case ($0.1400). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0700 to $0.1400) leaves room in how you read the outcome.
Key figures of Redsense Medical AB
How large is the market capitalisation of Redsense Medical AB (RDSNF)?
The market capitalisation of Redsense Medical AB is $8.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Redsense Medical AB (RDSNF)?
The price-to-sales ratio of Redsense Medical AB is 0.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Redsense Medical AB (RDSNF)?
Earnings per share at Redsense Medical AB are $−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Redsense Medical AB (RDSNF)?
The net margin of Redsense Medical AB is −29.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Redsense Medical AB (RDSNF)?
The return on equity (ROE) of Redsense Medical AB is −8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Redsense Medical AB (RDSNF)?
On an EBIT basis the return on assets of Redsense Medical AB is −19.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Redsense Medical AB (RDSNF)?
Revenue at Redsense Medical AB is growing +38.9% versus a year earlier (3y avg +18.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Redsense Medical AB (RDSNF) generate?
The free cash flow of Redsense Medical AB is −8.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Redsense Medical AB in the live analysis
One click puts Redsense Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.